Michael W. Bonney

Board Director

Director

Bristol Myers Squibb CoAlnylam Pharmaceuticals, Inc.

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 1 saleSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (1 ops.)

€4.3M

Latest filing published 19 Aug 2025 for ALNYLAM PHARMACEUTICALS, INC., €677k. Read the official filing

Filing timeline

BuySale

Michael W. Bonney

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Michael W. Bonney: trading record in brief

Michael W. Bonney (board member) discloses dealings in 2 companies, chiefly Alnylam Pharmaceuticals, Inc. and Bristol Myers Squibb Co. In total, 8 filings cover trades dated from 3 June 2021 to 18 August 2025.

No open-market purchase appears, only 1 sale worth €4.3M. Outside the open market, there are 1 share grant and 6 option exercises. In 2025 alone, the filings show no purchases and 1 sale.

The newest entry dates from 19 August 2025: an option exercise of €677k, in Alnylam Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.